“It’s like chemotherapy. If you have it all at once, you are going to kill the patient. You need to find a dose that won’t kill the patient.”
The patient being discussed by a senior capital markets banker in New York is the Argentine economy. The dispute that still rages domestically and internationally is about president Mauricio Macri’s medicine. How large should the dose of adjustment be? And just how quickly should the government implement its reforms?
Many abroad and in Argentina are in a favour of upping the speed at which the medicine is administered, especially in light of Macri’s success in last October’s mid-term elections.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
